The substantial dilution (~18%) from this overnight offering signals potential cash burn concerns or need to fund clinical development. Monitor upcoming quarterly results for cash runway updates and pipeline progress. The 60-day lock-up expiration in late December 2026 could create additional selling pressure.
Price Chart
Executive Summary
Arcus Biosciences closed a public offering of 16,428,572 shares of common stock at $17.50 per share, including full exercise of the underwriters' option, raising net proceeds of approximately $269.7 million. The offering was priced at a ~6% discount to the public offering price (underwriters paid $16.45/share) and dilutes existing shareholders by roughly 18% based on pre-offering share count. Proceeds will be used for general corporate purposes as described in the prospectus.
Key Facts
- Offering of 14,285,715 firm shares plus full exercise of 2,142,857 optional shares = 16,428,572 total shares issued
- Public offering price: $17.50 per share; underwriters paid $16.45 per share
- Net proceeds to company: approximately $269.7 million after underwriting discounts and estimated expenses
- Underwriters: Jefferies LLC, Leerink Partners LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Mizuho Securities USA LLC
- Lock-up period of 60 days from prospectus date for insiders listed on Schedule III
- Offering closed on October 23, 2026
- Shares listed on NYSE under ticker RCUS
Financial Impact
Dilutive equity offering of ~$270M net proceeds; ~18% dilution based on pre-offering share count (estimated ~90M shares outstanding pre-offer).
Risk Factors
- Significant dilution to existing shareholders (~18% increase in share count)
- Potential overhang from 60-day lock-up expiration in late December 2026
- No stated specific use of proceeds beyond general corporate purposes suggests possible operational cash needs
- Offering priced at $17.50 vs $16.45 underwriter purchase price indicates ~6% discount to market
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000050 |
| Document: a8kex51.htm | 0001724521-26-000050 |
| Document: 0001724521-26-000050-index-headers.html | 0001724521-26-000050 |
| Document: 0001724521-26-000050-index.html | 0001724521-26-000050 |
| Document: 0001724521-26-000050.txt | 0001724521-26-000050 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $18.47 | awaiting T+1 | — | $18.54 (−0.38%) |
Oct 22, 2026 3d ago | 424B5 | $19.36 | awaiting T+1 | — | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 424B5 | $19.36 $18.54 | ▲ +4.24% | ▲ +3.71% | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 8-K | $19.36 $18.54 | ▼ −4.24% | ▼ −3.71% | $18.54 (−4.24%) |
Oct 20, 2026 6d ago | 8-K | $23.75 $19.10 | ▼ −19.58% | ▼ −20.10% | $18.54 (−21.94%) |
Jul 9, 2026 15w ago | 144 | $28.92 $28.07 | ▼ −2.94% | ▼ −2.17% | $18.54 (−35.89%) |
Apr 21, 2026 26w ago | DEFA14A | $26.62 $25.13 | ▼ −5.60% | ▼ −5.20% | $18.54 (−30.35%) |
Apr 20, 2026 27w ago | 8-K | $22.74 $24.52 | ▼ −7.83% | ▼ −8.48% | $18.54 (+18.47%) |
Apr 8, 2026 28w ago | 144 | $23.28 $22.34 | ▼ −4.04% | ▼ −3.98% | $18.54 (−20.36%) |
Feb 25, 2026 34w ago | 8-K | $19.54 $20.37 | ▲ +4.25% | ▲ +4.73% | $18.54 (−5.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers